Pfizer, Inc. and Warner-Lambert Company v. Ranbaxy Pharmaceuticals and Teva Pharmaceuticals

Pfizer, Inc. and Warner-Lambert Company v. Ranbaxy Pharmaceuticals and Teva Pharmaceuticals

D.N.J. (2005)

On November 22, 2005, the Federal Circuit affirmed the District Court’s decision to grant preliminary injunction on behalf of our clients Pfizer and Warner Lambert, halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceutical Inc., and Ranbaxy Laboratories Limited. Judge Dickinson R. Debevoise of the U.S. District Court of New Jersey ordered Teva and Ranbaxy to immediately stop marketing the product which Teva launched in December 2004 under its own label as part of an agreement with Ranbaxy, finding that Pfizer was likely to prevail in its patent infringement suit. The judge also denied Ranbaxy’s and Teva’s request to stay the injunction. As a result of the ruling, Pfizer will seek damages resulting from lost sales.